The Role of b-Arrestins in Cancer - Progress in Molecular Biology and Translational Science - page 399

48. Lefkowitz RJ, Rajagopal K, Whalen EJ. New roles for beta-arrestins in cell signaling: not
just for seven-transmembrane receptors. Mol Cell . 2006;24(5):643- 652.
49. Li H, Sun X, LeSage G, et al. beta-Arrestin 2 regulates Toll-like receptor 4-mediated
apoptotic signalling through glycogen synthase kinase-3beta. Immunology . 2010;130
(4):556 - 563.
50. Ahn S, Kim J, Hara MR, Ren XR, Lefkowitz RJ. {beta}-Arrestin-2 mediates anti-
apoptotic signaling through regulation of BAD phosphorylation. J Biol Chem .

2009;284(13):8855- 8865.
51. Luan B, Zhang Z, Wu Y, Kang J, Pei G. Beta-arrestin2 functions as a phosphorylation-
regulated suppressor of UV-induced NF-kappaB activation. EMBO J . 2005;24
(24):4237- 4246.
52. Schaffner F, Ruf W. Tissue factor and PAR2 signaling in the tumor microenvironment.
Arterioscler Thromb Vasc Biol . 2009;29(12):1999- 2004.
53. Boucharaba A, Guillet B, Menaa F, et al. Bioactive lipids lysophosphatidic acid and
sphingosine 1-phosphate mediate breast cancer cell biological functions through distinct
mechanisms. Oncol Res . 2009;18(4):173- 184.
54. Boucharaba A, Serre CM, Guglielmi J, Bordet JC, Clezardin P, Peyruchaud O. The type
1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad
Sci USA . 2006;103(25):9643- 9648.
55. Peyruchaud O, Boucharaba A, Saulnier-Blache JS, Clezardin P. Lysophosphatidic acid: a
new link between blood platelets and bone metastasis. Med Sci . 2005;21(4):353 - 355.
56. Boucharaba A, Serre CM, Gres S, et al. Platelet-derived lysophosphatidic acid supports
the progression of osteolytic bone metastases in breast cancer. J Clin Invest . 2004;114
(12):1714- 1725.
57. Bonnans C, Flaceliere M, Grillet F, et al. Essential requirement for beta-arrestin2 in
mouse intestinal tumors with elevated Wnt signaling. Proc Natl Acad Sci USA .

2012;109(8):3047- 3052.
58. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin . 2012;62
(1):10- 29.
59. Heeschen C, Jang JJ, Weis M, et al. Nicotine stimulates angiogenesis and promotes
tumor growth and atherosclerosis. Nat Med . 2001;7(7):833- 839.
60. Wu Z, Tong W, Tan Z, Wang S, Lin P. The clinical significance of beta-arrestin 2
expression in the serum of non-small cell lung cancer patients. Zhongguo Fei Ai Za
Zhi . 2011;14(6):497 - 501.
61. Wang MT, Honn KV, Nie D. Cyclooxygenases, prostanoids, and tumor progression.
Cancer Metastasis Rev . 2007;26(3 - 4):525- 534.
62. Schneider C, Pozzi A. Cyclooxygenases and lipoxygenases in cancer. Cancer Metastasis
Rev . 2011;30(3- 4):277- 294.
63. Achiwa H, Yatabe Y, Hida T, et al. Prognostic significance of elevated cyclooxygenase 2
expression in primary, resected lung adenocarcinomas. Clin Cancer Res . 1999;5
(5):1001- 1005.
64. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated
cyclooxygenase-2 expression in breast cancer. Cancer Res . 2002;62(3):632- 635.
65. Kim JI, Lakshmikanthan V, Frilot N, Daaka Y. Prostaglandin E2 promotes lung cancer
cell migration via EP4-betaArrestin1-c-Src signalsome. Mol Cancer Res . 2010;8
(4):569 - 577.
66. Avritscher EB, Cooksley CD, Grossman HB, et al. Clinical model of lifetime cost of
treating bladder cancer and associated complications. Urology . 2006;68(3):549- 553.
67. Moussa O, Ashton AW, Fraig M, et al. Novel role of thromboxane receptors beta iso-
form in bladder cancer pathogenesis. Cancer Res . 2008;68(11):4097- 4104.